हिंदी में पढ़ें

Pfizer

Price control, ad-hoc regulatory changes may hamper pharma

Price control, ad-hoc regulatory changes may hamper pharma

Sun, Sep 02, 2018

The Indian pharma market (IPM) stood at Rs 121,833 crore at the end of financial year 2018, growing at 6.3 per cent over the last 12 months period. This represents a significant slowdown from the historic 13-14 per cent CAGR trends (2010-2016).

Pfizer ends research for new Alzheimer''s, Parkinson's drugs

Pfizer ends research for new Alzheimer''s, Parkinson's drugs

Mon, Jan 08, 2018

Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.

Stocks to watch today: Reliance, L&T, PNB Housing

Stocks to watch today: Reliance, L&T, PNB Housing

Mon, Nov 07, 2016

BSE Sensex closed at 27,274.15 points, down 0.57% on Friday November 4, 2016. While NSE Nifty lost 0.60% on the same day and closed at 8,433.75 points.

TRENDING NOW

US drugmaker Pfizer abandons plan to split into two companies; stock falls nearly 2%

US drugmaker Pfizer abandons plan to split into two companies; stock falls nearly 2%

Mon, Sep 26, 2016

US drugmaker Pfizer Inc, which has been considering a split into two companies for more than two years, said on Monday it would not do so because the move would not create any shareholder value.

Pfizer completes sale of 4 products deal to Piramal Enterprises

Pfizer completes sale of 4 products deal to Piramal Enterprises

Mon, Sep 26, 2016

Pfizer on Monday announced that it has completed its transaction deal for the sale of four products to Piramal Enterprises.

Asian stocks edge up, dollar dips as markets await Fed clues

Asian stocks edge up, dollar dips as markets await Fed clues

Tue, Aug 23, 2016

Fed fund futures imply around a 24% chance of an easing in September, rising to around 50% by December.

Pfizer to buy Medivation for $14 billion

Pfizer to buy Medivation for $14 billion

Mon, Aug 22, 2016

Pfizer Inc has agreed to buy Medivation Inc which is a biopharmaceutical company focused on developing and commercializing in the treatment for cancer. The merger will be for $81.50 a share in cash for a total enterprise value of approximately $14 billion.

Pfizer plans to bring more global drugs to India

Pfizer plans to bring more global drugs to India

Mon, Aug 15, 2016

"Except for a couple of CNS (central nervous system) products and one pain product, we are not really missing a major portfolio. We are looking at couple of global products, though they have gone all off LOE (loss of exclusivity) to reintroduce them into India, we are also looking at that aspect of this juncture," Pfizer India Managing Director S Sridhar told analysts.

Wall Street pulled down by tech, auto stocks

Wall Street pulled down by tech, auto stocks

Tue, Aug 02, 2016

Wall Street fell on Tuesday, with the S&P 500 and the Nasdaq having their worst day in more than a month, following weak economic data and losses in technology and consumer discretionary stocks.

Pharmaceutical sector set for wave of mergers, acquisitions: Study

Pharmaceutical sector set for wave of mergers, acquisitions: Study

Mon, May 30, 2016

After its failure to acquire Allergan, Pfizer recently announced plans to buy Anacor Pharmaceuticals

Pfizer to buy Anacor Pharma in Rs 34,000 crore deal

Pfizer to buy Anacor Pharma in Rs 34,000 crore deal

Mon, May 16, 2016

Pfizer will pay $99.25 per share for Anacor.

Pfizer expected to bid for acquisition of US cancer drug company Medivation

Pfizer expected to bid for acquisition of US cancer drug company Medivation

Wed, May 04, 2016

Medivation has not yet decided whether it should engage with Pfizer in negotiations and is in discussions with its financial and legal advisers

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x